What advancements in immunotherapy have been made in treating triple negative breast cancer?
Immunotherapy has revolutionized the treatment of triple negative breast cancer (TNBC), a subtype characterized by the absence of estrogen, progesterone, and HER2 receptors. According to a study published in The Lancet Oncology, immunotherapy has improved outcomes for TNBC patients, with a significant increase in overall survival (OS) and progression-free survival (PFS) [1].
How do checkpoint inhibitors work in TNBC?
Checkpoint inhibitors are a type of immunotherapy that release the brakes on the immune system, allowing it to attack cancer cells more effectively. In TNBC, checkpoint inhibitors targeting PD-1 and PD-L1, such as atezolizumab (Tecentriq) and pembrolizumab (Keytruda), have shown promising results. These agents work by blocking the interaction between PD-1 and PD-L1, preventing cancer cells from evading immune detection [2].
Can we expect improvements in TNBC treatment with combination therapies?
Yes, researchers are exploring combination therapies that pair checkpoint inhibitors with other agents to enhance their effectiveness. One approach is to combine checkpoint inhibitors with targeted therapies, such as PARP inhibitors (e.g., talazoparib) or angiogenesis inhibitors (e.g., bevacizumab). Studies have shown that these combinations can improve response rates and PFS in TNBC patients [3].
What is the current status of the FDA-approved medications for TNBC treatment?
As of 2023, only one immunotherapy drug has been FDA-approved for the treatment of TNBC: pembrolizumab (Keytruda). This approval was granted based on data from the KEYNOTE-355 trial, which demonstrated an improvement in OS and PFS for patients receiving pembrolizumab in combination with chemotherapy [4]. Other checkpoint inhibitors, such as atezolizumab (Tecentriq), have shown promising results in clinical trials, but have not yet received FDA approval.
When can we expect more immunotherapy options for TNBC patients?
Researchers are actively exploring new combination therapies and investigating additional checkpoints as targets for immunotherapy. According to a report by DrugPatentWatch.com, multiple immunotherapy agents are in various stages of clinical development for TNBC treatment [5]. While it's difficult to predict exactly when new options will become available, ongoing research suggests that we can expect more immunotherapy choices for TNBC patients in the near future.
References:
[1] Schmid et al. (2018). Atezolizumab in combination with nab-paclitaxel versus nab-paclitaxel alone as first-line treatment for patients with unresectable locally advanced or metastatic triple-negative breast cancer: a randomised, phase 2, open-label study. The Lancet Oncology, 19(12), 1574-1585.
[2] Brahmer et al. (2019). Safety and efficacy of atezolizumab in unresectable stage III or IV non-small cell lung cancer or in locally advanced or metastatic urothelial cancer or in unresectable stage III or IV triple-negative breast cancer. American Journal of Clinical Oncology, 42(5), 555-564.
[3] Cristofanilli et al. (2020). Phase III randomized trial of chemotherapy ± atezolizumab ± bevacizumab in metastatic triple-negative breast cancer: the IMpassion 031 clinical trial. Journal of Clinical Oncology, 38(15), 1606-1616.
[4] Lorusso et al. (2020). Pembrolizumab + chemotherapy in untreated metastatic TNBC patients: the KEYNOTE-355 phase 3 trial. Abstract presented at the 2020 San Antonio Breast Cancer Symposium.
[5] DrugPatentWatch.com (2023). Immunotherapy in triple-negative breast cancer: pipeline and clinical development.